Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib …
INTRODUCTION
Tofacitinib is a Janus kinase (JAK) 1-3 inhibitor first U.S. Food and Drug Administration (FDA) approved in 2012 for rheumatoid arthritis, with subsequent approval for psoriatic arthritis, ulcerative colitis, polyarticular course juvenile idiopathic arthritis, and ankylosing spondylitis in 2017, 2018, 2020, and 2021, respectively.1,2 In the last several years, oral tofacitinib … Continue reading "Refractory Alopecia Areata and Vitiligo Responding to Tofacitinib Monotherapy"
Next Steps in Derm, in partnership with ODAC Dermatology, Aesthetic and Surgical Conference, interviewed Dr. George Han (Vice President of the Dermatologic Society of Greater New York, member of the board of directors of the New York State Society of Dermatology and Dermatologic Surgery, and member of the Medical Board of the National Psoriasis Foundation), who offers tips on better directing pa … 
Chronic idiopathic urticaria is urticaria for greater than 6 weeks without an identifiable trigger. Cases relapse in 20% of patients for more than 5 years and be difficult to manage; however, omalizumab is a recently approved option for treatment of chronic idiopathic urticaria showing beneficial outcomes.1 Omalizumab is an injectable monoclonal antibody that has been FDA approved not just for chr … 
Dr. Vishal Patel (Assistant Professor of Dermatology and Director of the Cutaneous Oncology Program at George Washington University School of Medicine and Health Sciences) gave a thought-provoking talk at the 2022 ODAC Dermatology, Aesthetic & Surgical Conference about something we do nearly every day as dermatologists – full body skin exams. He started by reviewing the rising epidemic of sk … 
The November issue of the Journal of Drugs in Dermatology (JDD) focuses on lasers, lights sources, and devices featuring original articles and case reports exploring topics such as combination of platelet rich plasma and 1550 nm fractional laser for androgenetic alopecia, safety of combination laser procedures in single clinic visit, efficacy of a fractionated 1540 nm erbium glass laser in the tre … 